X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Ranbaxy: Better than its global peers? - Views on News from Equitymaster
StockSelect
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Ranbaxy: Better than its global peers?
Apr 5, 2006

The past one year has been a testing time for Ranbaxy due to intense competition and price erosion faced in its key market, the US. Its global peers such as Teva, Mylan and Watson have not been spared either. Since Ranbaxy is competing in the global generics space, in this article, we have analysed its performance vis--vis its international peers.

A look at the financials
(US$ m) (CY05/FY05) Teva Mylan* Watson Ranbaxy
Net sales 5,250 1,253 1,646 1,180
Net sales (3 year CAGR) 27.7% 4.3% 10.4% 11.5%
EBIDTA 1,522 347 425 86
EBIDTA margin (%) 29.0% 27.7% 25.8% 7.3%
Net profit 1,081 204 138 56
Net profit margin (%) 20.6% 16.2% 8.4% 4.8%
Net profit (3 year CAGR) 37.9% -7.9% -7.7% -26.9%
R&D expenditure 7.0% 7.0% 7.6% 8.8%
SG&A expenses 15.2% 20.7% 15.9% 25.5%

To Read the Full Story, Subscribe or Sign In


Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

RANBAXY LAB SHARE PRICE


Apr 1, 2015 (Close)

TRACK RANBAXY LAB

  • Track your investment in RANBAXY LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MARKET STATS